Protein Degraders in Cancer Treatment: What They Are and How They Work

Join us for an engaging Facebook Live discussion on the role of RET gene alterations (fusions and mutations) in cancers such as lung and thyroid cancer.

While current therapies, including tyrosine kinase inhibitors, are a cornerstone in treatment, there's a growing need for new solutions when these drugs lose their effectiveness. In this session, we will hear from Emily Walthall and Dr. Hilary Hammell from the RETpositive community as they share their insights and experiences.

Also joining us is Justin Drake, PhD, the 2024 RETpositive/LUNGevity Foundation awardee, who will dive into the world of protein degraders—a groundbreaking new class of drugs that show promise in preclinical cancer models. Dr. Drake is associate professor in the Department of Pharmacology and Urology at the University of Minnesota. He will explain how these innovative treatments work and their potential in the treatment of RET-positive cancers.

Upal Basu Roy, PhD, MPH, executive director of research at LUNGevity Foundation, will moderate this conversation. Don’t miss this chance to learn about new RET-targeted therapies!